This study is a component of a multi-center, double-blind, parallel clinical safety study. It will test the tolerances and efficacy of the thromboxane receptor antagonist, Ifetroban. Evidence clearly suggests that the production of thromboxane may play a role in the baso-spastic element of claudication. Using a standardized exercise protocol over twelve weeks, Ifetroban's effects will be evaluated at three different doses. The expected outcome is improved claudication time.
Showing the most recent 10 out of 577 publications